With regard to different detection methods of HER2 in ovarian cancer, positive HER2 expression status was a worse prognostic marker of overall survival in immunohistochemistry (IHC) group (n = 27, HR = 1.59, 95% CI = 1.28 to 1.98, H2 = 1.8; I2 = 68.2%, 95% CI = 54% to 79%). This evidence concerns the gene ERBB2 and ovarian cancer.